Qiming Weekly | Qiming Venture Partners Portfolio News: Top 10 Updates Vol.20, June 16, 2026

Editor's Note: In 2026, the Qiming Weekly gets a fresh upgrade with regular weekly updates, featuring only ten curated headlines from Qiming Venture Partners' portfolio companies — covering funding milestones and breakthrough developments.

Every step entrepreneurs take in the tide of technology and innovation deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower founders, and we invite you to join us in marking these milestone moments for our portfolio companies.

Funding News

01/

Daxiao Robotics Closes Angel+ Round

Qiming Venture Partners portfolio company Daxiao Robotics recently completed its Angel+ funding round, bringing its total raised in the first half of 2026 to several hundred million dollars. The new capital will primarily fund development of its world model and integrated "software-hardware" commercial solutions. Leveraging its human-centric environmental data collection approach, the company aims to accelerate breakthroughs and deployment of its Kaiwu world model in large-scale embodied AI training and edge-side direct-drive control — further cementing its global lead in world models. It will also build out full-stack, integrated solutions for smart retail, security patrol, cultural tourism, hospitality, and other commercial scenarios, deepening open collaboration with upstream and downstream partners to build an open, synergistic embodied AI ecosystem.

"Embodied AI represents the next era of artificial intelligence, and the 'strongest brain' built around world models is the key to unlocking it," said Xiaogang Wang, Chairman of Daxiao Robotics. "We will continue to pursue fundamental technology innovation with our mission of giving every robot a smart brain, translating cutting-edge embodied AI into new productive forces that drive industry forward and accelerate the arrival of embodied AI's 'ChatGPT moment.'"

02/

NOITOM Robotics Closes Pre-A++ Round

Qiming Venture Partners portfolio company NOITOM Robotics recently completed its Pre-A++ round, raising several hundred million RMB. The company expects to launch its next funding round soon.

"After months of detailed discussions and on-site due diligence, we selected a group of 'AI investment national team' institutions with rich data collection scenarios across multiple regions," said Dr. Ruoli Dai, Founder of NOITOM Robotics. "Solving embodied AI's data famine requires hard work, but it also needs fertile soil — and we're grateful they chose us, a team that lets its effort speak louder than its voice."

Major Partnerships

01/

Shengshu Technology and Huace Group Form Strategic Partnership

At the recent launch event for Huace's AIGC High-Tech Film and Television Production Center in Tonglu, Qiming Venture Partners portfolio company Shengshu Technology signed a strategic cooperation agreement with Huace Film & TV. The two sides will pursue deep collaboration around AI audiovisual production center development, AI video generation technology application, film and television content production, industry-education integration, and creator ecosystem building — guided by principles of "complementary strengths, ecosystem co-building, and industrial落地" — to jointly advance the convergence of AI and film and television.

The partnership will establish an "AI Audiovisual Production Center" within Huace Film & TV's technology industry-education demonstration zone, with Shengshu Technology's Vidu video generation large model and tool platform serving as the technical foundation. The center will explore AI virtual production combined with live-action filming to produce high-quality audiovisual content, while exporting AI video production capabilities to the industry. The two companies will also jointly establish a "Huace & Shengshu AI Film and Television Production" program at Zhejiang Huace Film and Television School, with a curriculum covering both traditional film directing, editing, and production techniques and AI video content creation. Together, they will cultivate a new generation of content creators with film and television aesthetics, AI tool proficiency, and hands-on industry experience.

02/

Shangyue Partners with Muyuan Industrial

Qiming Venture Partners portfolio company Shangyue recently signed an agreement with Muyuan Industrial Group for an SRM procurement management platform. The partnership will focus on digitalization, intelligence, and collaboration to drive cost reduction, efficiency gains, quality improvement, and risk control across Muyuan's procurement supply chain.

Drawing on its mature intelligent procurement platform and extensive experience with large enterprise deployments, Shangyue will develop a customized digital procurement solution tailored to Muyuan's business characteristics. The system will achieve closed-loop procurement workflows, controllable risk, and cost optimization, enhancing overall supply chain operational efficiency and core competitiveness.

Technology & Product Strength

01/

WeRide WRD 3.0 Debuts at Qualcomm Summit

At the 2026 Qualcomm Automotive Technology and Ecosystem Summit in Wuxi, Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD, 0800.HK) showcased its L2++ single-stack end-to-end solution WRD 3.0, alongside the debut of the GAC Aion N60 — the first mass-production passenger vehicle built on the Qualcomm Snapdragon SA8650 platform with WeRide's technology. The N60's ADAS technology comes from WeRide, and vehicles equipped with WRD 3.0 scored 102.81 points to win a fifth consecutive championship at the 2nd China Intelligent Driving Competition Hefei Station last month, setting a new record for consecutive wins.

Notably, the GAC Aion N60 is not only WeRide's first mass-production passenger vehicle with GAC but also marks WeRide's first commercial deployment of single-stack end-to-end technology on a Qualcomm Snapdragon platform. Powered by WeRide WRD 3.0, the N60 uses multi-target intent prediction and full-scene semantic recognition to proactively understand the behavioral states of different traffic participants. This highly human-like "thinking" enables the N60 to anticipate potential risks and dynamically adjust speed and path when facing non-motorized vehicles weaving through traffic, pedestrians darting across, urban villages, and multi-level interchanges — unstructured scenarios where it can maintain safety margins without the efficiency losses of excessive conservatism.

02/

DeepWay Completes Maersk Delivery

Qiming Venture Partners portfolio company DeepWay recently completed a delivery ceremony with Maersk, a global leader in integrated logistics, at Shanghai Lingang. Ten intelligent new-energy heavy-duty trucks are now in commercial operation, dedicated to container shuttle services between Maersk's Lingang integrated logistics flagship warehouse and Shanghai Yangshan Deep Water Port. With this delivery, Maersk will establish a low-carbon land transport link covering the "last mile" before export and "first mile" after import, using low-carbon, intelligent new capacity to build an efficient bridge between warehousing hubs and international maritime ports.

The scaled deployment in benchmark port logistics scenarios like Maersk has generated massive real-world operational data and corner-case extreme condition samples for DeepWay, effectively enhancing vehicle perception, decision-making, and execution capabilities in complex port environments and further refining the commercial deployment of advanced autonomous driving across diverse scenarios.

R&D Progress

01/

Imviva Biotech's IND Application Approved by FDA

Qiming Venture Partners portfolio company Imviva Biotech announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for CTA313, a dual-targeting CD19/BCMA allogeneic CAR-T cell therapy for B cell-mediated autoimmune diseases. This milestone marks Imviva's strategic expansion into autoimmune disease therapeutics.

The FDA-approved Phase 1b basket trial design will evaluate CTA313's safety, efficacy, and cellular pharmacokinetics across multiple B cell-mediated autoimmune diseases, including systemic lupus erythematosus (SLE), progressive multiple sclerosis (pMS), and autoimmune encephalitis (AE). This basket design enables efficient exploration of CTA313's potential across multiple indications while maintaining flexibility to advance promising indications into Phase 2 development.

02/

Belief BioMed's BBM-P002 Clinical Study Published in Nature Medicine

Qiming Venture Partners portfolio company Belief BioMed, an innovative gene therapy company, announced that early clinical study results for its self-developed BBM-P002 in mid-to-late stage Parkinson's disease patients have been published in the international journal Nature Medicine (IF=50). The paper, titled "Dual-target gene therapy in Parkinson's disease: a multicenter phase 1 trial," was conducted by teams led by Dr. Jun Liu at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, and Dr. Lu Shen at Xiangya Hospital, Central South University (ClinicalTrials.gov: NCT05822739).

The BBM-P002 study is a multicenter, single-arm, open-label safety and preliminary efficacy trial that enrolled 10 subjects across multiple dose cohorts. It evaluates the safety, tolerability, and efficacy of stereotactic bilateral putaminal injection of BBM-P002 for mid-to-late stage Parkinson's disease. Follow-up comprises a primary study phase of 52 weeks post-dosing and a long-term follow-up phase from 52 weeks to 5 years. All subjects have completed the 52-week primary study phase and entered long-term follow-up. The published data represents interim results after all subjects completed their 52-week primary study visits.

Product Launches

01/

Insta360 Launches 8K Leica Dual-Lens Gimbal Camera

Qiming Venture Partners portfolio company Insta360 (688775.SH) officially launched Luna Ultra, the industry's first flagship dual-lens gimbal camera. Featuring an AI triple-chip computing architecture and dual Leica optical lenses, the device captures 8K video with up to 12x zoom, priced from RMB 3,999 for a limited time in China with global availability.

Luna Ultra marks Insta360's entry into the handheld gimbal camera market. With two Leica Summicron optical lenses, its groundbreaking 8K Leica imaging system and product form factor completely redefines the creative boundaries of handheld gimbal cameras. The 1-inch 8K main sensor delivers outstanding image quality across day and night scenes thanks to its large sensor advantage; the 1/1.3-inch super telephoto lens supports up to 12x zoom and 6x lossless zoom; and the industry's first AI triple-chip configuration enables breakthrough 4K 60fps night video recording.

02/

Unisound Officially Releases Next-Generation General-Purpose LLM — U2

Qiming Venture Partners portfolio company Unisound (09678.HK) has officially released its next-generation general-purpose large language model, U2. As a native intelligent agent LLM designed for individuals, developers, and organizations, U2's technical philosophy is deliberately focused: high intelligence density × high token value. Rather than blindly stacking parameters, it pursues high intelligence density — delivering stronger capabilities with fewer activated resources. Rather than simply competing on output length, it pursues high token value — making every inference call closer to a deliverable result.

Unlike traditional LLMs that lean toward single-turn Q&A or short-chain generation, U2 emphasizes continuous execution capability for real-world tasks. In complex office work, software engineering, deep research, and multi-tool collaboration scenarios, U2 can autonomously decompose and advance 100+ step complex workflows, chaining together requirement understanding, task planning, environmental interaction, tool invocation, error correction, and result verification into a complete closed loop — moving from "giving answers" to "getting things done."

Past Issues

Qiming Perspectives | Duane Kuang, Qiming Venture Partners: Embrace the Cycle, Cross the Cycle — AI Will Be an Ultra-Long Technology Cycle Qiming Weekly | Top 10 Headlines from Qiming Venture Partners Portfolio Companies Vol. 18, 2026.6.2 Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including ChinaVenture's 2025 Top 4 Best VC Firms

Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since inception, the firm has focused on investing in early and growth-stage outstanding companies in Technology and Healthcare innovation.

To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, with more than 210 exiting via listings on the NYSE, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.

Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Genrix Bio (688520.SH), Insilico Medicine (03696.HK), Hope Medicine, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.